MedCity INVEST Precision Drugs brings collectively regional and nationwide stakeholders throughout healthcare, biopharma, and medtech to debate new developments in precision drugs, the fact on the bottom, and what must occur for extra widespread adoption and integration of those revolutionary applied sciences.
Click on right here to register now!
Right here’s what’s taking place on Day 2 of the net convention:
Software program Supporting Biopharma R&D 10:30-11:30 am ET
(Sponsored by Komodo Well being)
There may be lots of exercise within the space of software program corporations specializing in cell and gene remedy R&D. This panel will discover among the various approaches corporations are taking to enhance effectivity and avert pitfalls in therapeutic improvement.
Moderator: John Reites, CEO, THREAD Analysis
- Aswin Chandrakantan, MD, Chief Medical Officer and Head of Life Sciences, Komodo Well being
- Annie Harris, Director of Expertise Enablement, Covance
Biologics and the Provide Chain Ballet 1:00 pm- 2:00 pm ET
The pathway of delivering complicated therapies to their locations is peppered with pitfalls from the manufacturing course of to sustaining extraordinarily delicate parts in a managed surroundings in transit. This panel will spotlight how completely different organizations within the biopharma provide chain are addressing the inherent challenges of manufacturing and delivering cell and gene therapies and biologics.
Moderator: Frank Vinluan, Senior Reporter, MedCity Information
- Joe DePinto, Chief Business Officer, Vineti
- Jason Foster, CEO, Ori Biotech
- Claudia Zylberberg, PhD, Founder & CEO, Akron Biotechnology
Pitch Excellent Precision Drugs Half 2: Life Sciences: 3:30-5:00 pm
Shows by precision drugs startups and development stage corporations throughout diagnostics, biopharma and medtech. Three judges will hear pitches and ask questions.
The presenting corporations embrace:
Prenome is a girls’s well being firm centered on enhancing scientific outcomes with vanguard applied sciences in data-driven personalised drugs. Prenome’s platform allows the early identification of dangers and individualized interventions to decrease prices and enhance outcomes throughout the ladies’s well being care continuum with out reliance on costly therapies and therapeutics. The platform has been developed in collaboration with main specialists in girls’s well being and personalised drugs. Prenome is at present partnering with healthcare suppliers and payers to enhance affected person care by integrating the Prenome platform into routine workflow.
Nia Therapeutics is growing implantable mind stimulation machine for the remedy of reminiscence loss. Reminiscence loss impacts over 20M People with traumatic mind harm and degenerative illness, leading to vital decreases in productiveness and high quality of life. Nia’s proprietary medical machine platform makes use of mind sensing and synthetic intelligence to develop a customized remedy for every affected person based mostly upon their distinctive sample of mind exercise. Their know-how was developed on the College of Pennsylvania with $24M in funding from DARPA and the group has demonstrated proof of idea of their potential to enhance human reminiscence in neurosurgical sufferers. Nia’s first scientific goal is reminiscence loss as a result of traumatic mind harm, a $32 billion whitespace market.
Doloromics is a spin-out from the College of Texas at Dallas. Based in 2020, the aim of Doloromics is to establish novel drug targets for continual ache utilizing our proprietary DOLOReS algorithm.
SmartTab is engaged within the design, improvement and validation of subsequent technology wi-fi drug supply programs. The SmartTab know-how platform is a personalised wi-fi answer comprised of an ingestible capsule with a microprocessor, sensible polymer actuator, and lively components. SmartTab is on a mission to offer novel efficient therapies to enhance affected person outcomes and compliance.
OpalGenix’s patented genotype-based opioid threat prediction and scientific determination help platform, GPS-Opioid, empowers clinicians to personalize opioid and ache administration. Within the U.S., 30M grownup and pediatric sufferers are given opioids for ache aid after surgical procedures yearly. GPS-Opioid personalizes opioid choice and dosing to maximise ache aid and decrease opioid-related security dangers and prices. OpalGenix has accomplished pediatric scientific research, obtained >10 USPTO and European patent claims, and acquired discover of intent to fund an NIH STTR grant proposal.
The judges are:
- Adam Dakin, Managing Director, Dreamit Ventures
- Yizhen Dong, Accomplice, International Founders Capital
- Ben Johnson, Managing Director, Head of Early Stage Life Science, Silicon Valley Financial institution
Photograph: Joshua Blake, Getty Pictures